Discipline | Microbiology, pharmacology |
---|---|
Language | English |
Edited by | J. Peter Donnelly |
Publication details | |
History | 1975–present |
Publisher | |
Frequency | Monthly |
Hybrid and delayed (after 12 months) | |
3.9 (2023) | |
Standard abbreviations | |
ISO 4 | J. Antimicrob. Chemother. |
Indexing | |
CODEN | JACHDX |
ISSN | 0305-7453 (print) 1460-2091 (web) |
OCLC no. | 612059247 |
Links | |
The Journal of Antimicrobial Chemotherapy is a peer-reviewed medical journal which covers antimicrobial chemotherapy, including laboratory aspects and clinical use of antimicrobial agents. It is published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy and was established in 1975. In January 2015 J. Peter Donnelly (Radboud University Nijmegen Medical Centre) became the eighth editor-in-chief replacing Alan P. Johnson (Health Protection Agency, London, United Kingdom). [1] The journal has had two previous publishers. [1] All content is available for free after 12 months while authors also have the option to have their articles published immediately as open access. [2]
The Journal of Antimicrobial Chemotherapy was founded by David Williams in 1975, who was also its editor for its first six years. [3] [4]
The journal is abstracted and indexed in:
According to the Journal Citation Reports , the journal has a 2023 impact factor of 3.9. [10]
Sir Richard Brook Sykes is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation, and the trustees at King Edward VII's Hospital, and chancellor of Brunel University. As of June 2021, he is chair of the UK's Vaccine Taskforce, where he is responsible for overseeing the delivery of the COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.
Fusidic acid, sold under the brand name Fucidin among others, is a steroid antibiotic that is often used topically in creams or ointments and eyedrops but may also be given systemically as tablets or injections. As of October 2008, the global problem of advancing antimicrobial resistance has led to a renewed interest in its use.
Imipenem is a synthetic β-lactam antibiotic belonging to the carbapenems chemical class. developed by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. Carbapenems are highly resistant to the β-lactamase enzymes produced by many multiple drug-resistant Gram-negative bacteria, thus playing a key role in the treatment of infections not readily treated with other antibiotics. It is usually administered through intravenous injection.
Temocillin is a β-lactamase-resistant penicillin introduced by Beecham, marketed by Eumedica Pharmaceuticals as Negaban. It is used primarily for the treatment of multiple drug-resistant, Gram-negative bacteria.
It is a 6-methoxy penicillin; it is also a carboxypenicillin.
Apramycin is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius.
Grepafloxacin was an oral broad-spectrum fluoroquinolone antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn worldwide from markets in 1999, due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death.
Critical Care Medicine is a peer-reviewed monthly medical journal in the field of intensive care medicine. The journal was established in 1973 with William C. Shoemaker as the founding editor. It is the official publication of the Society of Critical Care Medicine and is published by Lippincott Williams & Wilkins. The journal's editor-in-chief is Timothy G. Buchman.
In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible in vitro growth of bacteria or fungi. MIC testing is performed in both diagnostic and drug discovery laboratories.
Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.
Antimicrobial Agents and Chemotherapy is a peer-reviewed scientific journal published by the American Society for Microbiology. It covers antimicrobial, antiviral, antifungal, and antiparasitic agents and chemotherapy. The editor-in-chief is Cesar A. Arias. It was established in 1972 by Gladys Lounsbury Hobby.
Acinetobacter baumannii is a typically short, almost round, rod-shaped (coccobacillus) Gram-negative bacterium. It is named after the bacteriologist Paul Baumann. It can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived (nosocomial) infection. While other species of the genus Acinetobacter are often found in soil samples, it is almost exclusively isolated from hospital environments. Although occasionally it has been found in environmental soil and water samples, its natural habitat is still not known.
Clinical Microbiology Reviews is a peer-reviewed medical journal covering the areas of clinical microbiology, immunology, medical microbiology, infectious diseases, veterinary microbiology, and microbial pathogenesis. It is a delayed open access journal, full content is accessible via PubMed Central and the journal's website after a 12-month embargo. In April 2015, the journal transitioned to a continuous online publication model. The journal became online-only in January 2018. The final print issue was published in October 2017. According to the Journal Citation Reports, the journal has a 2023 impact factor of 19.0. The journal was established in January 1988. The founding editor was Josephine A. Morello. Editorial board structure changed in 1992 and Morello became editor-in-chief. Betty Ann Forbes was appointed editor-in-chief in 1997. Irving Nachamkin was appointed editor-in-chief in 2002 until 2012. Jo-Anne H. Young served as editor-in-chief from 2012 to 2022. The current editor-in-chief is Graeme Forrest. It is the ninth journal established and published by the American Society for Microbiology.
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.
The Journal of Immunology is a biweekly peer-reviewed medical journal that publishes basic and clinical studies in all aspects of immunology. Established in 1916, it changed its name to Journal of Immunology, Virus Research and Experimental Chemotherapy from 1943 to 1949, then returned to the original Journal of Immunology in 1950. It is the official journal of the American Association of Immunologists. The editor-in-chief is Gail A. Bishop.
The Journal of Infectious Diseases is a peer-reviewed biweekly medical journal published by Oxford University Press on behalf of the Infectious Diseases Society of America. It covers research on the pathogenesis, diagnosis, and treatment of infectious diseases, on the microbes that cause them, and on immune system disorders. Cynthia Sears, an expert on gut infections, was appointed editor-in-chief in 2023.
The British Journal of Pharmacology is a biweekly peer-reviewed medical journal covering all aspects of experimental pharmacology. It is published for the British Pharmacological Society by Wiley-Blackwell. It was established in 1946 as the British Journal of Pharmacology and Chemotherapy, and originally published by the British Medical Association. The journal obtained its current title in 1968.
Febrile neutropenia is the development of fever, often with other signs of infection, in a patient with neutropenia, an abnormally low number of neutrophil granulocytes in the blood. It is an oncologic emergency, and is the most common serious complication in patients with hematopoietic cancers or receiving chemotherapy for cancer. The term neutropenic sepsis is also applied, although it tends to be reserved for patients who are less well. In 50% of cases, an infection is detectable; bacteremia is present in approximately 20% of all patients with this condition.
Mecillinam (INN) or amdinocillin (USAN) is an extended-spectrum penicillin antibiotic of the amidinopenicillin class that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria. It is used primarily in the treatment of urinary tract infections, and has also been used to treat typhoid and paratyphoid fever. Because mecillinam has very low oral bioavailability, an orally active prodrug was developed: pivmecillinam.
HIV Resistance Response Database Initiative (RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world.